A First-Ever Guideline for Kids With Axial Spondyloarthritis
Axial spondyloarthritis (axSpA) is an autoimmune condition that causes chronic inflammation primarily in the spine and sacroiliac joints, leading to pain and stiffness that often starts subtly and worsens gradually. It's chronically under-recognized in general, but the problem is especially pronounced in children and teenagers, since standard imaging like X-rays often doesn't show clear signs of joint damage early in the disease course, meaning young patients can go undiagnosed and untreated for years while the disease quietly progresses.
On June 24, 2026, the American College of Rheumatology (ACR) released updated treatment guidelines addressing this problem directly. The update includes a refresh of the existing 2019 ACR guidelines for adult axSpA, alongside something new: a standalone companion guideline specifically developed for juvenile axial spondyloarthritis, the first time this pediatric population has had its own dedicated guidance rather than being an afterthought within the adult recommendations.
One of the most practical changes involves how diagnosis should actually work at different ages. For adults, the guidelines recommend starting with sacroiliac joint X-rays, and only moving to MRI if those results are inconclusive. For children, the guidelines flip that order, recommending MRI without contrast as the first-line imaging approach, reflecting the reality that X-rays are simply less reliable for catching this disease early in a still-developing skeleton.
On treatment, the guidelines now consider TNF inhibitors and IL-17 inhibitors, two different classes of biologic drugs, as equivalent first-line options rather than favoring one over the other, giving doctors and patients more flexibility to choose based on individual factors. JAK inhibitors, a newer and more broadly immune-modulating class of drugs, are recommended but generally reserved for after these first-line biologics have been tried. The guidelines also explicitly recommend against routinely using older, conventional synthetic DMARDs for axial, spine-focused, disease unless a patient also has peripheral arthritis or other symptoms outside the joints.
For families of children with unexplained, persistent back or hip stiffness, having a dedicated juvenile guideline matters because it gives pediatric rheumatologists clearer, evidence-based direction rather than adapting adult protocols on a case-by-case basis. That, in turn, should help more young patients get accurately diagnosed and started on appropriate treatment before structural joint damage has a chance to set in. If your child has ongoing, unexplained joint stiffness, this update is worth bringing up directly with their rheumatologist, particularly if past evaluations relied only on X-rays that came back looking normal.